TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Operating Income

Profit from core operations after operating expenses, before interest and taxes.

TELA Bio, Inc.NASDAQ: TELA

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income remains negative

Q2 FY2026 operating income was -$9.28M, compared with -$9.08M a year earlier. Trailing-twelve-month operating income was -$34.01M.

Context

  • Operating income amounted to 42.0% of revenue in FY2025, down 7.2 pp from a year earlier.
  • Operating income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 4 analysts of -$26.56M (+21.3%) for the fiscal year ending Dec 2026, a step up from the +1.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$9.28M+11.8% QoQ
Last fiscal yearDec 2025
-$33.76M+1.1% YoY
LTMJun 2026
-$34.01M+8.7% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.2%-11.0%-8.7 pp
1 year+1.1%+21.3%+20.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(33.76M) USD
Year-over-year change
+1.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 operating income of -$34.01M is the 8th highest of the 9 companies compared; the peer median is -$18.39M.
  • Its year-over-year change of +8.7% is the 4th highest of 9, against a peer median of -6.6%.
  • Operating income amounts to 42.6% of revenue for TELA, versus a peer median of 404.8%.
TELA Competitors Peer median
Operating Income for TELA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDAISpectral AI, Inc.LTM Mar 2026-$9.92M -85.9%—59.4%
SRTSSensus Healthcare, Inc.LTM Mar 2026-$12.02M -570.0%—53.3%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-$12.9M -15.3%—912.4%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$17.19M +2.1%—749.7%
CUECue Biopharma, Inc.LTM Mar 2026-$19.58M +52.4%—59.8%
EQEquillium, Inc.LTM Mar 2026-$20.38M -42.0%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026-$34.01M +41.4%——
TELATELA Bio, Inc.LTM Jun 2026-$34.01M +8.7%—42.6%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$60.57M +20.8%—18182.8%
Peer median (excluding TELA) -$18.39M-6.6%—404.8%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.46M41.42M58.45M69.3M80.28M
Cost of Revenue10.65M14.37M18.34M22.81M25.93M
Gross Profit18.81M27.04M40.11M46.49M54.34M
Gross Margin63.9%65.3%68.6%67.1%67.7%
Research & Development6.74M8.94M9.62M8.81M9.22M
Selling, General & Admin41.52M57.11M74.57M79.37M78.88M
Operating Expenses48.26M66.05M84.19M80.6M88.1M
Depreciation & Amortization535K1.19M808K1.01M1.01M
EBITDA(29.14M)(39.06M)(40.63M)(31.68M)(32.35M)
EBITDA Margin-98.9%-94.3%-69.5%-45.7%-40.3%
Operating Income(29.45M)(39.01M)(44.08M)(34.12M)(33.76M)
Operating Margin-100.0%-94.2%-75.4%-49.2%-42.0%
Interest Income00000
Interest Expense3.6M4.05M5.22M5.29M5.25M
Other Income / Expenses(3.83M)(5.29M)(2.59M)(3.87M)(4.85M)
Income Before Tax(33.28M)(44.3M)(46.66M)(37.99M)(38.6M)
Pre-Tax Margin-112.9%-106.9%-79.8%-54.8%-48.1%
Income Tax Expense000(144K)230K
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Net Margin-112.9%-106.9%-79.8%-54.6%-48.4%
EPS (Basic)(2.30)(2.73)(2.04)(1.33)(0.83)
EPS (Diluted)(2.30)(2.73)(2.04)(1.33)(0.83)
Weighted Avg Shares14.47M16.27M22.87M28.53M46.95M
Weighted Avg Shares (Diluted)14.47M16.27M22.87M28.53M46.95M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.